Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.27
Percentage change -1.10	%

Peers: JNJ MRK PFE ABBV BMY LLY GSK NVS SAN AZN

| Held by: VTI IJH VB VBR VXF SDY REGL MDY SMIG VIG

Index	-	P/E	-	EPS (ttm)	-1.11	Insider Own	0.40%	Shs Outstand	136.50M	Perf Week	2.85%
Market Cap	3.30B	Forward P/E	8.00	EPS next Y	3.02	Insider Trans	-12.02%	Shs Float	135.89M	Perf Month	-4.95%
Income	-151.50M	PEG	-	EPS next Q	0.95	Inst Own	97.76%	Short Float	3.31%	Perf Quarter	-4.43%
Sales	4.39B	P/S	0.75	EPS this Y	-0.12%	Inst Trans	6.38%	Short Ratio	3.04	Perf Half Y	-12.86%
Book/sh	33.45	P/B	0.72	EPS next Y	17.35%	ROA	-1.34%	Short Interest	4.50M	Perf Year	-26.93%
Cash/sh	10.73	P/C	2.25	EPS next 5Y	-	ROE	-3.16%	52W Range	23.14 - 33.96	Perf YTD	-5.95%
Dividend Est.	1.10 (4.55%)	P/FCF	21.75	EPS past 5Y	-	ROI	-1.68%	52W High	-28.80%	Beta	0.54
Dividend TTM	1.10 (4.57%)	Quick Ratio	1.77	Sales past 5Y	-0.53%	Gross Margin	36.09%	52W Low	4.49%	ATR (14)	0.72
Dividend Ex-Date	Nov 29, 2024	Current Ratio	2.56	EPS Y/Y TTM	-22246.00%	Oper. Margin	6.52%	RSI (14)	37.93	Volatility	3.37% 3.04%
Employees	9140	Debt/Eq	1.08	Sales Y/Y TTM	-5.59%	Profit Margin	-3.45%	Recom	2.00	Target Price	34.00
Option/Short	Yes / Yes	LT Debt/Eq	0.98	EPS Q/Q	-213.78%	Payout	-	Rel Volume	0.48	Prev Close	24.45
Sales Surprise	-3.08%	EPS Surprise	-0.18%	Sales Q/Q	-3.18%	Earnings	Nov 06 BMO	Avg Volume	1.48M	Price	24.18
SMA20	-3.08%	SMA50	-8.47%	SMA200	-11.88%	Trades		Volume	173,888	Change	-1.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-14-25	Downgrade	Argus	Buy → Hold
Jan-06-25	Downgrade	Piper Sandler	Overweight → Neutral	$34 → $27
Sep-24-24	Resumed	Jefferies	Hold	$50 → $30
Nov-17-23	Initiated	Piper Sandler	Overweight	$37
Mar-07-23	Initiated	Canaccord Genuity	Buy	$49
Sep-14-22	Upgrade	Argus	Hold → Buy	$46
Sep-06-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$48 → $54
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform	$59
Sep-30-21	Upgrade	Jefferies	Hold → Buy	$45 → $63
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform	$51
Jan-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$59 → $49
Apr-17-20	Downgrade	Argus	Buy → Hold
Mar-24-20	Upgrade	JP Morgan	Neutral → Overweight	$57
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform	$54 → $52
Mar-18-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$58
Oct-11-19	Upgrade	Argus	Hold → Buy
Mar-20-19	Initiated	SunTrust	Hold
Nov-13-18	Downgrade	Berenberg	Buy → Hold
Aug-10-18	Reiterated	Stifel	Hold	$92 → $87
Jul-30-18	Downgrade	Argus	Buy → Hold

Show Previous Ratings

Jan-21-25 07:50AM	Heres White Falcon Capitals Investment Thesis for Perrigo Company plc (PRGO) (Insider Monkey)
Jan-06-25 08:00AM	Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer (PR Newswire)
Dec-06-24 11:31AM	Perrigo (PRGO) Up 5.6% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-11-24 09:15AM	Perrigo (PRGO) International Revenue Performance Explored (Zacks)
Nov-07-24 02:09AM	Perrigo Co PLC (PRGO) Q3 2024 Earnings Call Highlights: Strategic Savings and EPS Growth Amid ... (GuruFocus.com)
04:51PM	Loading…
Nov-06-24 04:51PM	Analyst Report: Perrigo Company plc (Morningstar Research) +7.73%
09:51AM	Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations (PR Newswire)
09:51AM	/C O R R E C T I O N -- Perrigo Company plc/ (PR Newswire)
09:30AM	Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:40AM	Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates (Zacks)
06:47AM	Perrigo: Q3 Earnings Snapshot (Associated Press Finance)
Nov-01-24 02:57PM	Perrigo Announces Quarterly Dividend (PR Newswire)
Oct-30-24 10:01AM	Perrigo (PRGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-23-24 10:37AM	Perrigo Company plc (PRGO): Leading OTC Health Products with Strong Growth in Infant Formula (Insider Monkey)
09:00AM	Perrigo to Release Third Quarter 2024 Financial Results on November 6, 2024 (PR Newswire)
08:00AM	Loading…
Oct-15-24 08:00AM	WNBA Star Napheesa Collier Joins Team Opill for Candid Conversations on Women's Health (PR Newswire)
Sep-26-24 08:30AM	Perrigo Announces Good Start and Dr. Browns Brand Partnership and Launch of Infant Formula Portfolio (PR Newswire)
Sep-17-24 04:48PM	PERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY (PR Newswire)
Sep-13-24 07:00PM	Insider Sale: Director Katherine Doyle Sells 8,954 Shares of Perrigo Co PLC (GuruFocus.com)
Sep-12-24 09:00AM	PERRIGO ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY (PR Newswire)
06:52AM	What Makes Perrigo Company plc (PRGO) an Attractive Bet? (Insider Monkey)
Sep-05-24 01:07AM	Perrigo Company plc (PRGO): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-04-24 08:00AM	Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary (PR Newswire)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 08:30AM	Perrigo to Attend the Piper Sandler Growth Frontiers Conference (PR Newswire)
Aug-19-24 08:30AM	Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer (PR Newswire)
Aug-14-24 06:00AM	Stress on Shelvesthe Battle for Space in Store Aisles (The Wall Street Journal)
Aug-09-24 06:21AM	Perrigo recalls 16,500 cans of its infant formula (Reuters)
Aug-05-24 09:15AM	Interpreting Perrigo (PRGO) International Revenue Trends (Zacks)
Aug-02-24 02:16PM	Analyst Report: Perrigo Company plc (Morningstar Research)
10:42AM	Loading…
10:42AM	Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View (Zacks)
09:30AM	Compared to Estimates, Perrigo (PRGO) Q2 Earnings: A Look at Key Metrics (Zacks)
07:54AM	Perrigo Reaffirms FY24 Adj. EPS Guidance; Updates Sales Outlook (RTT News)
07:45AM	Perrigo (PRGO) Q2 Earnings Top Estimates (Zacks)
06:43AM	Perrigo: Q2 Earnings Snapshot (Associated Press Finance)
06:31AM	Perrigo Reports Second Quarter 2024 Financial Results From Continuing Operations (PR Newswire)
Aug-01-24 09:00AM	Perrigo Announces Quarterly Dividend (PR Newswire)
Jul-31-24 09:30AM	Perrigo to Attend the Canaccord Genuity 44th Annual Growth Conference (PR Newswire)
Jul-29-24 12:10PM	Perrigo (PRGO) to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-26-24 10:00AM	Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-23-24 06:59AM	Does Perrigo (PRGO) Have a Good Growth Potential? (Insider Monkey)
Jul-19-24 09:15AM	Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024 (PR Newswire)
Jul-10-24 08:00AM	Perrigo Completes Divestment of HRA Pharma Rare Diseases Business (PR Newswire)
Jun-06-24 11:31AM	Why Is Perrigo (PRGO) Down 15.1% Since Last Earnings Report? (Zacks)
May-30-24 11:28AM	3 Underrated Dividend Stocks Worth Your Attention 'Unknown' But High Yield Potential (Benzinga)
May-28-24 08:03AM	Perrigo to Attend Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference (PR Newswire)
May-13-24 11:53AM	Understanding Perrigo (PRGO) Reliance on International Revenue (Zacks)
10:11AM	Perrigo Company plc (NYSE:PRGO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 04:31PM	Analyst Report: Perrigo Company plc (Morningstar Research) -9.81%
11:23AM	Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates (Zacks)
10:53AM	PRGO Stock Earnings: Perrigo Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:30AM	Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:28AM	Perrigo's Q1 Adjusted Earnings, Net Sales Drop (MT Newswires)
08:02AM	Perrigo Co PLC (PRGO) Q1 2024 Earnings: Adjusted EPS Exceeds Expectations Despite Sales Dip (GuruFocus.com)
06:51AM	Perrigo Reaffirms 2024 Outlook - Update (RTT News)
06:40AM	Perrigo: Q1 Earnings Snapshot (Associated Press Finance)
06:31AM	Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations (PR Newswire)
06:28AM	Perrigo Announces Executive Transition for its Consumer Self-Care International (CSCI) Business (PR Newswire)
May-06-24 09:16AM	Insights Into Perrigo (PRGO) Q1: Wall Street Projections for Key Metrics (Zacks)
May-01-24 09:42AM	Perrigo Announces Quarterly Dividend (PR Newswire)
Apr-30-24 10:59AM	Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-25-24 10:41AM	Perrigo Receives Binding Offer to Sell HRA Pharma Rare Diseases Business for Up to $295 Million (MT Newswires)
06:00AM	Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to 275 Million (PR Newswire)
Apr-23-24 08:09AM	Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024 (PR Newswire)
Apr-15-24 08:15AM	Here's Why Perrigo Company PLC (PRGO) Stock Slumped in Q1 (Insider Monkey)
Apr-11-24 09:03AM	The WNBA has partnered with Glossier and Skimsnow its added Opill, the new over-the-counter birth control (Fortune)
Apr-09-24 12:30PM	Opill and WNBA Team Up for Groundbreaking Partnership (PR Newswire)
Apr-04-24 04:37PM	CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors (Reuters)
Mar-28-24 11:30AM	Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report? (Zacks)
Mar-18-24 10:00AM	Prepare for Takeoff With Perrigo (GuruFocus.com)
Mar-05-24 10:48AM	Perrigo Company plc (NYSE:PRGO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-04-24 11:23AM	First over-the-counter birth control pill in US begins shipping to stores (Associated Press Finance)
08:00AM	Perrigo Commences Shipments of Opill to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States (PR Newswire)
08:00AM	Over-the-Counter Birth Control Pill to Be Available Within Weeks on Retail Shelves (The Wall Street Journal)
Mar-03-24 10:32AM	Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices (InvestorPlace)
Feb-29-24 04:21PM	Perrigo to Attend UBS Global Consumer and Retail Conference (PR Newswire)
Feb-28-24 06:13AM	Analyst Report: Perrigo Company plc (Morningstar Research)
Feb-27-24 12:32PM	Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View (Zacks) -15.14%
09:30AM	Compared to Estimates, Perrigo (PRGO) Q4 Earnings: A Look at Key Metrics (Zacks)
07:12AM	Perrigo Co PLC (PRGO) Posts Record Net Sales in Q4 and FY 2023, Launches Efficiency Program (GuruFocus.com)
06:49AM	Perrigo: Q4 Earnings Snapshot (Associated Press Finance)
06:48AM	Perrigo Guides FY24 Well Below Estimates - Update (RTT News)
06:30AM	Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program (PR Newswire)
Feb-26-24 04:30PM	Perrigo Increases its Quarterly Dividend (PR Newswire)
09:16AM	Ahead of Perrigo (PRGO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-20-24 01:32PM	Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-13-24 08:16AM	Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024 (PR Newswire)
Dec-07-23 11:31AM	Perrigo (PRGO) Up 2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-29-23 08:54AM	Perrigo Announces Early Results of Cash Tender Offer for Notes (PR Newswire)
Nov-28-23 01:04PM	Insider Buying Alert: EVP & CHRO Robert Willis Acquires Shares of Perrigo Co PLC (GuruFocus.com)
Nov-16-23 05:16AM	Insider Confidence: Eduardo Bezerra's Purchase of Perrigo Co PLC Shares (GuruFocus.com)
Nov-15-23 05:03AM	Insider Buying: CEO Patrick Lockwood-Taylor Acquires 11,000 Shares of Perrigo Co PLC (GuruFocus.com) +5.16%
Nov-10-23 09:16AM	Perrigo Announces Cash Tender Offer for Notes (PR Newswire)
Nov-08-23 02:38PM	Perrigo Company plc (NYSE:PRGO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 02:16PM	Analyst Report: Perrigo Company plc (Morningstar Research)
11:53AM	Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View (Zacks)
09:30AM	Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:56AM	Midday movers: Uber Technologies, Intel, DR Horton and more (Investing.com)
07:10AM	Perrigo Co PLC (PRGO) Reports Double-Digit Growth in Gross Profit, Operating Income, and EPS ... (GuruFocus.com)
06:47AM	Perrigo: Q3 Earnings Snapshot (Associated Press Finance)

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KINDLER JEFFREY B	Director	Dec 09 '24	Sale	28.27	17,598	497,495	5,409	Dec 10 10:45 AM
KINDLER JEFFREY B	Director	Dec 09 '24	Proposed Sale	28.27	17,598	497,426		Dec 09 04:24 PM
Schmelter Triona	EVP & President CSCA	Oct 04 '24	Option Exercise	24.93	3,611	90,022	3,141	Oct 17 05:00 PM
Doyle Katherine C.	Director	Sep 13 '24	Sale	27.30	8,954	244,444	6,009	Sep 13 03:28 PM
Doyle Katherine C.	Director	Sep 13 '24	Proposed Sale	27.30	8,954	244,444		Sep 13 10:03 AM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Aug 26 '24	Sale	29.40	13,000	382,246	20,553	Aug 28 05:17 PM
RONALD CRAIG JANISH	Insider / Exec VP of Global Op	Aug 26 '24	Proposed Sale	29.40	13,000	382,246		Aug 26 04:07 PM
Andersen Svend	EVP & President CHCI	Aug 20 '24	Sale	27.75	28,300	785,279	73,553	Aug 21 09:20 AM
Andersen Svend	EVP & President CHCI	Aug 20 '24	Sale	27.43	6,683	183,281	7,000	Aug 21 09:20 AM
Andersen Svend	Officer	Aug 20 '24	Proposed Sale	27.86	20,500	571,130		Aug 20 01:09 PM
HANSON KYLE	Officer	Aug 07 '24	Proposed Sale	28.40	1,890	53,667		Aug 07 12:02 PM
Lockwood-Taylor Patrick	CEO	Jul 10 '24	Option Exercise	27.16	28,326	769,334	48,826	Jul 11 12:34 PM
Ives Alison	EVP & Chief Scientific Officer	Jul 08 '24	Option Exercise	25.72	920	23,662	18,930	Jul 10 09:51 AM
Bezerra Eduardo Guarita	EVP & Chief Financial Officer	Jun 07 '24	Option Exercise	26.94	4,532	122,092	16,563	Jun 11 01:44 PM
Andersen Svend	EVP & President CHCI	May 28 '24	Buy	27.90	1,000	27,900	101,853	May 31 05:04 PM
Parker Geoffrey M.	Director	May 15 '24	Option Exercise	30.22	8,764	264,848	24,469	May 16 07:28 PM
O'Connor Donal	Director	May 15 '24	Option Exercise	30.22	8,764	264,848	29,694	May 16 07:28 PM
Doyle Katherine C.	Director	May 15 '24	Option Exercise	30.22	8,764	264,848	19,170	May 16 07:27 PM
ASHFORD ORLANDO D	Director	May 15 '24	Option Exercise	30.22	10,955	331,060	20,992	May 16 07:27 PM
Alford Bradley A	Director	May 15 '24	Option Exercise	30.22	8,764	264,848	40,217	May 16 07:27 PM
Karaboutis Adriana	Director	May 15 '24	Option Exercise	30.22	8,764	264,848	26,686	May 16 07:26 PM
Manzone Albert	Director	May 15 '24	Option Exercise	30.22	8,764	264,848	11,612	May 16 07:26 PM
KINDLER JEFFREY B	Director	May 15 '24	Option Exercise	30.22	8,764	264,848	27,214	May 16 07:26 PM
Mann Erica L	Director	May 15 '24	Option Exercise	30.22	8,764	264,848	21,665	May 16 07:26 PM
Quinn Grainne	EVP, Chief Medical Officer	Mar 07 '24	Option Exercise	29.69	2,249	66,773	22,248	Mar 08 09:57 PM
Quinn Grainne	EVP, Chief Medical Officer	Mar 06 '24	Option Exercise	28.09	1,759	49,410	20,914	Mar 08 09:57 PM
Willis Robert	EVP & CHRO	Mar 07 '24	Option Exercise	29.69	2,163	64,219	32,595	Mar 08 09:34 PM
Willis Robert	EVP & CHRO	Mar 06 '24	Option Exercise	28.09	1,759	49,410	31,347	Mar 08 09:34 PM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Mar 07 '24	Option Exercise	29.69	2,942	87,348	34,439	Mar 08 09:18 PM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Mar 06 '24	Option Exercise	28.09	2,300	64,607	32,190	Mar 08 09:18 PM
HANSON KYLE	EVP & General Counsel	Mar 06 '24	Option Exercise	28.09	3,518	98,821	12,284	Mar 08 08:52 PM
Farrington Thomas	EVP and CIO	Mar 06 '24	Option Exercise	28.09	1,881	52,837	11,389	Mar 08 08:17 PM
Bezerra Eduardo Guarita	EVP & Chief Financial Officer	Mar 06 '24	Option Exercise	28.09	4,870	136,798	13,298	Mar 08 07:51 PM
Ives Alison	EVP & Chief Scientific Officer	Mar 06 '24	Option Exercise	28.09	2,030	57,023	17,402	Mar 08 07:36 PM
Ives Alison	EVP & Chief Scientific Officer	Mar 07 '24	Option Exercise	29.69	1,746	51,839	18,536	Mar 08 07:36 PM
Andersen Svend	EVP & President CHCI	Mar 07 '24	Option Exercise	29.69	5,468	162,345	100,853	Mar 08 07:18 PM
Andersen Svend	EVP & President CHCI	Mar 06 '24	Option Exercise	28.09	3,788	106,405	95,385	Mar 08 07:18 PM
Ives Alison	EVP & Chief Scientific Officer	Mar 05 '24	Option Exercise	27.26	1,698	46,287	14,144	Mar 07 09:58 PM
Ives Alison	EVP & Chief Scientific Officer	Mar 05 '24	Buy	27.26	2,490	67,877	16,122	Mar 07 09:58 PM
Ives Alison	EVP & Chief Scientific Officer	Feb 29 '24	Buy	26.44	1,545	40,850	12,446	Mar 07 09:54 PM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Mar 05 '24	Option Exercise	27.26	2,071	56,455	22,262	Mar 07 09:28 PM
Willis Robert	EVP & CHRO	Mar 05 '24	Option Exercise	27.26	1,279	34,866	26,755	Mar 07 09:10 PM
Quinn Grainne	EVP, Chief Medical Officer	Mar 05 '24	Option Exercise	27.26	1,583	43,153	15,646	Mar 07 09:00 PM
Farrington Thomas	EVP and CIO	Mar 05 '24	Option Exercise	27.26	1,693	46,151	4,516	Mar 07 08:49 PM
Andersen Svend	EVP & President CHCI	Mar 05 '24	Option Exercise	27.26	3,411	92,984	72,152	Mar 07 08:31 PM
Willis Robert	EVP & CHRO	Feb 29 '24	Buy	25.87	6,000	155,220	25,105	Mar 01 02:31 PM
Willis Robert	EVP & CHRO	Mar 01 '24	Buy	26.30	371	9,757	25,476	Mar 01 02:31 PM
Lockwood-Taylor Patrick	CEO	Feb 29 '24	Buy	26.54	9,500	252,168	20,500	Feb 29 01:39 PM

Open in Screener

PGEN

Precigen Inc

Jan 22 • 10:49AM ET

1.15

Dollar change -0.03
Percentage change -2.54	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX REGN GILD ILMN INCY SRPT BLUE ARWR

| Held by: VTI IWM VXF IWN IBB SCHA VTWO IWC FESM CNCR

Index	RUT	P/E	-	EPS (ttm)	-0.55	Insider Own	44.16%	Shs Outstand	292.87M	Perf Week	5.99%
Market Cap	336.80M	Forward P/E	-	EPS next Y	-0.21	Insider Trans	22.31%	Shs Float	163.53M	Perf Month	61.36%
Income	-139.56M	PEG	-	EPS next Q	-0.07	Inst Own	26.03%	Short Float	10.67%	Perf Quarter	20.66%
Sales	3.96M	P/S	85.05	EPS this Y	-20.51%	Inst Trans	7.57%	Short Ratio	12.65	Perf Half Y	-28.35%
Book/sh	0.19	P/B	6.08	EPS next Y	55.74%	ROA	-101.81%	Short Interest	17.45M	Perf Year	-10.16%
Cash/sh	0.10	P/C	11.76	EPS next 5Y	-	ROE	-137.46%	52W Range	0.65 - 1.93	Perf YTD	2.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.94%	ROI	-232.08%	52W High	-40.41%	Beta	1.64
Dividend TTM	-	Quick Ratio	1.63	Sales past 5Y	-15.17%	Gross Margin	-101.65%	52W Low	76.57%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	1.63	EPS Y/Y TTM	-49.25%	Oper. Margin	-2406.26%	RSI (14)	59.59	Volatility	7.10% 12.98%
Employees	202	Debt/Eq	0.10	Sales Y/Y TTM	-41.38%	Profit Margin	-3521.68%	Recom	1.80	Target Price	5.33
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-9.17%	Payout	-	Rel Volume	0.74	Prev Close	1.18
Sales Surprise	2.32%	EPS Surprise	-4.29%	Sales Q/Q	-30.89%	Earnings	Nov 14 AMC	Avg Volume	1.38M	Price	1.15
SMA20	10.20%	SMA50	25.33%	SMA200	-2.65%	Trades		Volume	248,449	Change	-2.54%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight	$7
Feb-25-21	Initiated	Stifel	Buy	$13
Feb-22-21	Initiated	Wells Fargo	Overweight	$14
Feb-18-21	Initiated	B. Riley Securities	Buy	$10
May-08-20	Initiated	H.C. Wainwright	Buy	$5

Jan-13-25 07:00AM	Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire) -8.94%
Jan-09-25 08:30AM	Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-30-24 07:00AM	Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire) +28.47%
Dec-27-24 09:00AM	Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock (PR Newswire)
Nov-14-24 04:30PM	Precigen Reports Third Quarter 2024 Financial Results and Business Updates (PR Newswire) -7.11%
04:05PM	Loading…
Nov-12-24 04:05PM	Precigen to Participate in the Stifel 2024 Healthcare Conference (PR Newswire) -5.04%
Sep-16-24 04:30PM	Precigen to Participate in the 2024 Cantor Global Healthcare Conference (PR Newswire)
Aug-14-24 04:05PM	Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates (PR Newswire)
01:54PM	Hedge Fund and Insider Trading News: Nelson Peltz, Jana Partners, Whitebox Advisors, Caxton Associates LP, Altium Capital, Soros Fund Management, Elliott Investment Management, Balyasny Asset Management, Precigen Inc (PGEN), Vulcan Materials Company (VMC), and More (Insider Monkey)
Aug-09-24 08:00AM	Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th (PR Newswire) -13.39%
Aug-07-24 09:30PM	Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock (PR Newswire) -12.59% +7.63%
Aug-06-24 04:04PM	Precigen Announces Proposed $30 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch (PR Newswire)
Jul-23-24 08:01AM	Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch (PR Newswire)
Jun-03-24 09:30AM	Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response (PR Newswire) +11.43%
05:00PM	Loading…
May-23-24 05:00PM	Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting (PR Newswire)
May-14-24 05:20PM	Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.11%
04:05PM	Precigen Reports First Quarter 2024 Financial Results and Business Updates (PR Newswire)
08:21AM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:05PM	Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting (PR Newswire)
Apr-24-24 10:20AM	Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting (PR Newswire)
09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Mar-28-24 04:05PM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-24 08:20AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-20-24 10:07AM	Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM	PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:31PM	Precigen Inc (PGEN) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Precigen Reports Full Year 2023 Financial Results and Business Updates (PR Newswire)
Mar-12-24 04:05PM	Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Mar-05-24 04:05PM	Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th (PR Newswire)
04:05PM	Loading…
Feb-06-24 04:05PM	Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-16-24 08:05AM	Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission (PR Newswire)
Jan-08-24 08:30AM	Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.53%
Jan-02-24 12:40PM	Hedge Fund and Insider Trading News: David Einhorn, Bill Ackman, D. E. Shaw, Steve Cohen, Rob Citrone, Saba Capital, HighPeak Energy, Inc (HPK), Precigen Inc (PGEN), and More (Insider Monkey) +5.22%
Dec-18-23 04:05PM	Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.74%
Nov-29-23 04:05PM	Precigen to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-09-23 04:55PM	Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs (PR Newswire) -13.49%
Nov-07-23 04:05PM	Precigen to Participate in the Stifel 2023 Healthcare Conference (PR Newswire) +12.93%
Sep-19-23 04:05PM	Precigen to Participate in Upcoming Leading Investor and Industry Conferences (PR Newswire) -8.33% +6.06%
Aug-09-23 08:00AM	Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 (PR Newswire) +6.90%
07:05AM	Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval (PR Newswire)
Aug-03-23 04:05PM	Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th (PR Newswire) -6.67%
Jun-20-23 07:30AM	Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Jun-05-23 04:05PM	Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients (PR Newswire)
Jun-03-23 12:00PM	Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers (PR Newswire)
May-31-23 08:05AM	Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer (PR Newswire)
May-10-23 08:00AM	Precigen Reports First Quarter 2023 Financial Results and Business Updates (PR Newswire)
May-03-23 08:30AM	Precigen to Announce First Quarter 2023 Financial Results on May 10th (PR Newswire) +8.85%
Apr-26-23 04:05PM	Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy at the 2023 ASCO Annual Meeting (PR Newswire)
Apr-17-23 09:01AM	Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023 (PR Newswire) +10.48%
Apr-03-23 04:30PM	Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® (PR Newswire) +5.66% -8.04%
Mar-29-23 08:05AM	Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors (PR Newswire) +15.44%
Mar-28-23 08:05AM	Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium (PR Newswire)
Mar-06-23 04:05PM	Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (PR Newswire) +17.39%
Feb-07-23 08:00AM	Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response (News Direct)
Jan-30-23 02:34PM	Germantown's Precigen raises $75M to advance treatments for rare diseases (American City Business Journals)
Jan-27-23 04:05PM	Precigen Announces Closing of Public Offering of Common Stock (PR Newswire)
Jan-24-23 10:40PM	Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock (PR Newswire) -24.66%
04:05PM	Precigen Announces Proposed $75.0 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (PR Newswire)
Jan-11-23 06:45PM	Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.64%
Jan-04-23 04:05PM	Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse Immunotherapy in Recurrent Respiratory Papillomatosis (PR Newswire) +5.41%
Dec-27-22 08:00AM	Precigens Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy (News Direct) -9.29%
Dec-19-22 04:05PM	Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.70%
Dec-12-22 07:01PM	Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients (PR Newswire)
Nov-16-22 05:07AM	Bullish: Analysts Just Made A Noticeable Upgrade To Their Precigen, Inc. (NASDAQ:PGEN) Forecasts (Simply Wall St.) -6.15%
Nov-09-22 04:05PM	Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs (PR Newswire) -8.13% +21.09%
Nov-02-22 04:30PM	Precigen to Announce Third Quarter 2022 Financial Results on November 9th (PR Newswire)
Sep-21-22 04:30PM	Precigen Names Rutul R. Shah Chief Operating Officer (PR Newswire) -13.81%
Sep-01-22 08:05AM	Precigen to Participate in the 2022 Wells Fargo Healthcare Conference (PR Newswire)
Aug-22-22 08:05AM	Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics (PR Newswire)
Aug-08-22 04:05PM	Precigen Reports Second Quarter and First Half 2022 Financial Results (PR Newswire) +12.68%
Aug-05-22 08:36AM	Investors in Precigen (NASDAQ:PGEN) from five years ago are still down 89%, even after 32% gain this past week (Simply Wall St.)
Aug-01-22 04:05PM	Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th (PR Newswire) +9.09%
Jul-06-22 08:09AM	Reston audience measurement company comScore names its next CEO (American City Business Journals) -9.88%
Jul-05-22 08:05AM	Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics (PR Newswire) +14.89%
Jun-27-22 04:05PM	Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit (PR Newswire)
May-17-22 04:05PM	Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference (PR Newswire)
May-14-22 08:15AM	Need To Know: Analysts Are Much More Bullish On Precigen, Inc. (NASDAQ:PGEN) Revenues (Simply Wall St.)
May-11-22 06:29AM	Earnings Update: Precigen, Inc. (NASDAQ:PGEN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts (Simply Wall St.) -7.75%
May-09-22 04:05PM	Precigen Reports First Quarter 2022 Financial Results and Business Updates (PR Newswire) -8.00% +12.17%
May-02-22 03:00PM	Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +5.26%
Apr-04-22 08:05AM	Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire) +11.45%
Apr-03-22 03:40PM	What Type Of Shareholders Make Up Precigen, Inc.'s (NASDAQ:PGEN) Share Registry? (Simply Wall St.)
Mar-01-22 08:00AM	Precigen Reports Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Feb-02-22 10:10AM	Further weakness as Precigen (NASDAQ:PGEN) drops 10% this week, taking five-year losses to 88% (Simply Wall St.) -10.38%
Feb-01-22 09:38PM	AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ... (GuruFocus.com)
Jan-24-22 02:48PM	It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. (American City Business Journals)
Jan-12-22 04:30PM	Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-11-22 10:00AM	Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher (Zacks)
Jan-05-22 04:05PM	Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire) -10.47%
Dec-13-21 05:05PM	Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire)
Dec-01-21 07:56AM	A US$64m market cap addition is just what Precigen, Inc. (NASDAQ:PGEN) insiders like to see after purchasing stock worth US$3.7m (Simply Wall St.)
Nov-24-21 08:38AM	Is the Options Market Predicting a Spike in Precigen (PGEN) Stock? (Zacks) +11.57%
Nov-10-21 04:05PM	Precigen to Present at the Stifel 2021 Virtual Healthcare Conference (PR Newswire) -10.72%
Nov-04-21 09:15AM	Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse Therapies (PR Newswire)
Nov-01-21 03:01PM	Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for (Zacks) +6.42%
Oct-27-21 04:38PM	Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments (PR Newswire) +10.22%
Oct-26-21 08:05AM	Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors (PR Newswire)
Oct-12-21 08:05AM	Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer (PR Newswire)

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Perez Jeffrey Thomas	SVP, IP Affairs	Aug 09 '24	Buy	0.85	58,823	50,000	743,097	Aug 13 05:09 PM
KIRK RANDAL J	Director	Aug 09 '24	Buy	0.85	23,529,411	19,999,999	64,547,214	Aug 13 04:15 PM
KIRK RANDAL J	Director	Mar 09 '24	Option Exercise	0.00	213,675	0	32,051,461	Mar 12 05:36 PM

PRGO

Perrigo Company plc

PGEN

Precigen Inc

Upgrade your FINVIZ experience